Approval · Notice of Compliance 1352 · 2000
ESTALIS: Notice of Compliance 1352
Issued March 13, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1352
- Date
- March 13, 2000
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Progestin-estrogen
Products in this notice
Medicinal ingredients
- ESTRADIOL 0.62 MG per PAD
- NORETHINDRONE ACETATE 2.7 MG per PAD
- ESTRADIOL 0.51 MG per PAD
- NORETHINDRONE ACETATE 4.8 MG per PAD